menu search

PALI / FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study

FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study
Palisade Bio Inc (NASDAQ: PALI) has received a "Study May Proceed" letter from the FDA for a Phase 3 trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery. The trial will enroll approximately 600 subjects. Read More
Posted: Mar 22 2022, 12:30
Author Name: Benzinga
Views: 101958

PALI News  

Why Is Palisade Bio (PALI) Stock Down 46% Today?

By InvestorPlace
September 7, 2023

Why Is Palisade Bio (PALI) Stock Down 46% Today?

Palisade Bio (NASDAQ: PALI ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. Palisade Bio more_horizontal

Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up

By Zacks Investment Research
September 7, 2023

Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up

Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies. more_horizontal

Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies

By Market Watch
September 6, 2023

Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies

Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant P more_horizontal

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

By Zacks Investment Research
April 6, 2023

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function more_horizontal

Why Is Palisade Bio (PALI) Stock Up 36% Today?

By InvestorPlace
March 31, 2023

Why Is Palisade Bio (PALI) Stock Up 36% Today?

Palisade Bio (NASDAQ: PALI ) stock is on the rise Friday after the biopharmaceutical company got an upgrade from an analyst. Maxim Group is behind tod more_horizontal

What Makes Palisade Bio, Inc. (PALI) a New Buy Stock

By Zacks Investment Research
March 29, 2023

What Makes Palisade Bio, Inc. (PALI) a New Buy Stock

Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Bu more_horizontal

Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event

By GlobeNewsWire
January 9, 2023

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

By Zacks Investment Research
November 23, 2022

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal more_horizontal


Search within

Pages Search Results: